查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲传染病分子诊断市场预测至 2030 年 - 区域分析 - 按类型（护理点检测和实验室检测）、最终用户、应用、疾病类型、感染类型
市场调查报告书
商品编码
1494290

欧洲传染病分子诊断市场预测至 2030 年 - 区域分析 - 按类型（护理点检测和实验室检测）、最终用户、应用、疾病类型、感染类型

Europe Molecular Diagnostics for Infectious Disease Market Forecast to 2030 - Regional Analysis - by Type (Point-of-Care Testing and Laboratory Testing), End User, Application, Disease Type, Infection Type
出版日期: | 出版商: The Insight Partners | 英文 162 Pages | 订单完成后即时交付

价格

2022年欧洲传染病分子诊断市值为23.4642亿美元，预计2030年将达到59.484亿美元；预计2022年至2030年复合年增长率为12.3%。

分子诊断在兽医传染病的应用不断增加，推动了欧洲传染病分子诊断市场

能够在早期阶段检测新出现的动物传染病的诊断技术对于减少与此类疾病爆发相关的经济损失至关重要。聚合酶炼式反应 (PCR) 仍然是全球检测动物病原体最广泛使用的分子检测方法。这种类型的诊断方法易于使用、成本效益高、灵敏度高、特异性强，能够进行大量检测。

护理点诊断 (POCD) 是简单、快速、可携式的诊断设备，可在现场检测疾病状态。近年来，实时PCR（qPCR）已转变为POCD平台。这些全自动平台结合了核酸萃取、热循环和现场报告结果。例如，Enigma Diagnostics的MiniLab是一个10-35公斤的分子诊断平台，可在现场携带，用于验证猪瘟病毒、禽流感病毒、猪瘟病毒和口蹄疫病毒。英国Primerdesign Ltd的genesig检测试剂盒提供冷冻干燥qPCR检测试剂盒，用于诊断62种牛、42种马、47种猪、60种禽、40种犬和26种猫病原体用于研究目的。同样，Boster 提供 Bosterbio qPCR 试剂盒，可检测多达 48 个单独或混合样本。它用于基因表现谱分析、目标 DNA 定量、微生物检测、病毒或细菌病原体负荷测定以及基于探针的 qPCR 的引子对性能评估。

因此，用于诊断动物细菌、病毒、真菌和寄生虫感染的分子诊断方法（例如PCR和qPCR）可以取代传统方法（例如血清学、显微镜和基于培养的技术）。

欧洲传染病分子诊断市场概述

欧洲传染病分子诊断市场分为德国、英国、法国、义大利、西班牙、奥地利、比利时、荷兰、卢森堡及欧洲其他国家。该地区在全球传染病分子诊断市场中占有重要份额，预计 2022 年至 2030 年复合年增长率将达到显着水准。欧洲市场的成长归因于生命科学研究的热潮和政府对传染病检测投资的增加。根据罗伯特·科赫研究所发表的一篇文章中的资料，2021 年德国登记了约 3,900 例结核病病例。此外，每年进行披衣菌和淋病检测的访客人数从 17%（2017 年）增加到 42%（2020 年）。根据巴斯德研究所的数据，在法国，流感每年影响 200-800 万人； 10,000-15,000 名患者死于流感。由于每年季节性爆发，它已成为一个公共卫生问题。该国其他病毒感染也在增加。根据巴斯德研究所的数据，有 134,000 人患有慢性丙型肝炎病毒 (HCV) 感染，并且每年新增约 4,000 例新病例。据世界卫生组织称，2020 年，义大利报告约 13,786 人死于传染病和寄生虫病。同样，约 1,303 例爱滋病毒病例被诊断出，发生率为每 10 万居民 2.2 例。根据人口资料局的数据，2022 年义大利人口老化率为24%，预计到2040 年将达到30%。等。

欧洲传染病分子诊断市场收入及 2030 年预测（百万美元）

欧洲传染病分子诊断市场区隔

欧洲传染病分子诊断市场根据类型、最终用户、应用、疾病类型、感染类型和国家进行细分。

根据类型，欧洲传染病分子诊断市场分为即时检测和实验室检测。到2022年，实验室检测领域将占据欧洲传染病分子诊断市场更大的市场。

依最终用户划分，欧洲传染病分子诊断市场分为即时检测和实验室检测。现场护理测试进一步分为人体测试和兽医测试。同样，实验室测试进一步分为人体测试和兽医测试。到2022年，人体检测部分（按现场检测）将占据更大的欧洲传染病分子诊断市场。 。

根据应用，欧洲传染病分子诊断市场分为即时检测和实验室检测。即时检测进一步细分为单一病原体的检测、两种或多种病原体的检测、新出现的新型感染的评估、生物威胁製剂和疾病相关生物标记的监测和早期检测以及抗菌素抗药性分析。同样，实验室检测进一步分为患者分层、药物治疗方案选择、毒性避免、治疗监测和疾病易感性检测。透过即时检测对单一病原体进行检测，将在 2022 年占据欧洲最大的传染病分子诊断市场。年疾病市场占有率。

根据疾病类型，欧洲传染病分子诊断市场分为即时检测和实验室检测。护理点检测进一步细分为败血症（例如泌尿生殖系统/肺/伤口）、假体关节感染、心内膜炎、性传染病、单核细胞增多症、A 型链球菌等。同样，实验室检测进一步分为败血症、人工关节感染、心内膜炎、性传染病、披衣菌、胃肠道感染、结核、H1N1病毒等。以床边检测计算，STD 细分市场将在2022 年占据欧洲最大的传染病分子诊断市场。份额。

根据感染类型，欧洲传染病分子诊断市场分为即时检测和实验室检测。即时检测进一步细分为细菌、病毒、真菌等。同样，实验室检测进一步分为细菌、病毒、真菌等。根据即时检测，细菌细分市场将在 2022 年占据欧洲最大的传染病分子诊断市场。

依国家/地区划分，欧洲传染病分子诊断市场分为德国、英国、法国、义大利、西班牙、奥地利、比利时、荷兰、卢森堡和欧洲其他国家。 2022年，德国将主导欧洲传染病分子诊断市场。

Abbott Laboratories、bioMerieux SA、Bruker Corp、Danaher Corp、DiaSorin SpA、F. Hoffmann-La Roche Ltd、Hologic Inc、Molzym GmbH & Co KG、Siemens Healthineers AG 和 Thermo Fisher Scientific Inc 是该领域的一些领先公司。病分子诊断市场。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：欧洲传染病分子诊断市场 - 主要产业动态

  • 市场驱动因素：
    • 全球传染病发生率激增
    • 分子诊断在兽医传染病的应用不断增加
  • 市场限制
    • 与分子测试相关的局限性
  • 市场机会
    • 分子诊断技术的进步
  • 未来的趋势
    • 个人化医疗中传染病的分子诊断
  • 影响分析：

第 5 章：传染病分子诊断市场 - 欧洲市场分析

  • 欧洲传染病分子诊断市场收入，2022 - 2030

第 6 章：欧洲传染病分子诊断市场 - 收入和 2030 年预测 - 按类型

  • 概述
  • 2022 年和 2030 年欧洲传染病分子诊断市场收入份额（按类型）（%）
  • 即时检测
  • 实验室测试

第 7 章：欧洲传染病分子诊断市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 2022 年和 2030 年欧洲传染病分子诊断市场收入份额（按最终用户分類的即时检测和实验室检测）（%）

第 8 章：欧洲传染病分子诊断市场 - 收入和 2030 年预测 - 按应用

  • 概述
  • 2022 年和 2030 年按应用分類的传染病分子诊断市场收入份额（按应用划分）（%）
  • 即时检测
  • 实验室测试

第 9 章：欧洲传染病分子诊断市场 - 收入和 2030 年预测 - 按疾病类型

  • 概述
  • 欧洲传染病分子诊断市场收入份额（按疾病类型分類的即时检测），2022 年和 2030 年（%）
  • 即时检测
  • 实验室测试

第 10 章：欧洲传染病分子诊断市场 - 收入和 2030 年预测 - 按感染类型

  • 概述
  • 欧洲传染病分子诊断市场收入份额（按感染类型分類的即时检测），2022 年和 2030 年（%）
  • 即时检测
  • 实验室测试

第 11 章：欧洲传染病分子诊断市场 - 国家分析

  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 奥地利
  • 比利时
  • 卢森堡
  • 荷兰人
  • 欧洲其他地区

第 12 章：产业格局

  • 概述
  • 市场上公司采取的成长策略，(%)
  • 有机发展
    • 概述
  • 无机发展
    • 概述

第 13 章：公司简介

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • Danaher Corp
  • Hologic Inc
  • Siemens Healthineers AG
  • Bruker Corp
  • Molzym GmbH & Co KG
  • DiaSorin SpA

第 14 章：附录

Product Code: BMIRE00029840

The Europe molecular diagnostics for infectious disease market was valued at US$ 2,346.42 million in 2022 and is expected to reach US$ 5,948.40 million by 2030; it is estimated to grow at a CAGR of 12.3% from 2022 to 2030.

Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases Fuels the Europe Molecular Diagnostics for Infectious Disease Market

Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential for reducing economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally for detecting animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, highly sensitive, and specific, with the ability to detect at a high volume.

Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating swine fever virus, avian influenza virus, classical swine fever virus, and foot-and-mouth disease virus for research purposes. The genesig detection kits of Primerdesign Ltd, UK, supplies lyophilized qPCR assay kits for the diagnosis of 62 bovine, 42 equine, 47 porcine, 60 avian, 40 canine, and 26 feline pathogens for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR.

Thus, molecular diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals can replace the conventional methods such as serological, microscopic, and culture-based techniques.

Europe Molecular Diagnostics for Infectious Disease Market Overview

The European molecular diagnostics for infectious disease market is segmented into Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe. The region holds a significant share of the global molecular diagnostics for infectious disease market and is expected to register a notable CAGR during 2022-2030. The market growth in Europe is attributed to an upsurge in life science research and an increase in government investments in testing infectious diseases. According to the data published in an article by the Robert Koch Institute, ~3,900 tuberculosis cases were registered in Germany in 2021. According to this study, ~5% of the test-site visitors in Germany had STD. Moreover, the number of annual visitors for chlamydia and gonorrhea tests had increased from 17% (2017) to 42% (2020). As per the INSTITUT PASTEUR, in France, influenza affects 2-8 million people each year; 10,000-15,000 patients succumb to death due to influenza. It has become a public health issue due to its seasonal outbreaks every year. Other viral infections are also on the rise in the country. As per INSTITUT PASTEUR, 134,000 people are living with chronic hepatitis C virus (HCV) infection, with the addition of ~4,000 new cases annually. According to the WHO, in 2020, ~13,786 deaths were reported due to infectious and parasitic diseases in Italy. Similarly, ~1,303 HIV cases were diagnosed with an incidence of 2.2 per 100,000 residents. As per the Population Reference Bureau, the aging population in Italy was 24% in 2022, which is expected to reach 30% by 2040. Techniques that are used in molecular diagnostic applications are core molecular biology methods such as PCR amplification, sequencing, nucleic acid isolation and quantification, and STR analysis.

Europe Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

Europe Molecular Diagnostics for Infectious Disease Market Segmentation

The Europe molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Europe molecular diagnostics market for infectious disease market share in 2022.

The Europe molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Europe molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Europe molecular diagnostics market for infectious disease market share in 2022.

Based on application, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.

Based on country, the Europe molecular diagnostics for infectious disease market is categorized into Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe. Germany dominated the Europe molecular diagnostics for infectious disease market in 2022.

Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Molzym GmbH & Co KG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe molecular diagnostics for infectious disease market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics

  • 4.1 Market Drivers:
    • 4.1.1 Surging Prevalence of Infectious Disease Globally
    • 4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
  • 4.2 Market Restraints
    • 4.2.1 Limitations Associated with Molecular Testing
  • 4.3 Market Opportunities
    • 4.3.1 Advancements in Molecular Diagnostics Technologies
  • 4.4 Future Trends
    • 4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
  • 4.5 Impact Analysis:

5. Molecular Diagnostic for Infectious Diseases Market - Europe Market Analysis

  • 5.1 Europe Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030

6. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Type

  • 6.1 Overview
  • 6.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
  • 6.3 Point-of-Care Testing
    • 6.3.1 Overview
    • 6.3.2 Point-of-Care Testing: Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Laboratory Testing
    • 6.4.1 Overview
    • 6.4.2 Laboratory Testing: Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by End User

  • 7.1 Overview
  • 7.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
    • 7.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    • 7.2.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)

8. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
  • 8.3 Point-of-Care Testing
    • 8.3.1 Overview
    • 8.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
  • 8.4 Laboratory Testing
    • 8.4.1 Overview
    • 8.4.2 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)

9. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Disease Type

  • 9.1 Overview
  • 9.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
  • 9.3 Point-of-Care Testing
    • 9.3.1 Overview
    • 9.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
      • 9.3.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
  • 9.4 Laboratory Testing
    • 9.4.1 Overview
    • 9.4.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
      • 9.4.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)

10. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Infection Type

  • 10.1 Overview
  • 10.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
  • 10.3 Point-of-Care Testing
    • 10.3.1 Overview
    • 10.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
  • 10.4 Laboratory Testing
    • 10.4.1 Overview
    • 10.4.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

11. Europe Molecular Diagnostic for Infectious Diseases Market - Country Analysis

  • 11.1 Europe Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
    • 11.1.1 Overview
    • 11.1.2 Europe Molecular Diagnostic for Infectious Diseases Market, by Country
      • 11.1.2.1 UK
        • 11.1.2.1.1 UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.1.2 UK: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.1.3 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.1.4 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.1.5 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.1.6 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.1.7 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.1.7.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.1.8 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.1.8.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.1.9 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.1.10 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.2 Germany
        • 11.1.2.2.1 Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.2.2 Germany: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.2.3 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.2.4 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.2.5 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.2.6 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.2.7 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.2.7.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.2.8 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.2.8.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.2.9 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.2.10 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.3 France
        • 11.1.2.3.1 France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.3.2 France: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.3.3 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.3.4 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.3.5 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.3.6 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.3.7 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.3.7.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.3.8 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.3.8.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.3.9 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.3.10 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.4 Italy
        • 11.1.2.4.1 Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.4.2 Italy: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.4.3 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.4.4 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.4.5 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.4.6 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.4.7 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.4.7.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.4.8 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.4.8.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.4.9 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.4.10 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.5 Spain
        • 11.1.2.5.1 Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.5.2 Spain: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.5.3 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.5.4 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.5.5 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.5.6 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.5.7 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.5.7.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.5.8 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.5.8.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.5.9 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.5.10 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.6 Austria
        • 11.1.2.6.1 Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.6.2 Austria: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.6.3 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.6.4 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.6.5 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.6.6 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.6.7 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.6.7.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.6.8 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.6.8.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.6.9 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.6.10 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.7 Belgium
        • 11.1.2.7.1 Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.7.2 Belgium: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.7.3 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.7.4 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.7.5 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.7.6 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.7.7 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.7.7.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.7.8 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.7.8.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.7.9 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.7.10 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.8 Luxembourg
        • 11.1.2.8.1 Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.8.2 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.8.3 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.8.4 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.8.5 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.8.6 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.8.7 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.8.7.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.8.8 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.8.8.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.8.9 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.8.10 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.9 The Netherlands
        • 11.1.2.9.1 The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.9.2 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.9.3 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.9.4 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.9.5 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.9.6 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.9.7 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.9.7.1 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.9.8 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.9.8.1 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.9.9 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.9.10 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.10 Rest of Europe
        • 11.1.2.10.1 Rest of Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.10.2 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.10.3 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.10.4 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.10.5 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.10.6 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.10.7 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.10.7.1 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.10.8 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.10.8.1 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.10.9 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.10.10 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Abbott Laboratories
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Thermo Fisher Scientific Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 bioMerieux SA
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Danaher Corp
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Hologic Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Siemens Healthineers AG
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bruker Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Molzym GmbH & Co KG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 DiaSorin SpA
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Molecular Diagnostic for Infectious Diseases Market Segmentation
  • Table 2. Europe Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. UK Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. UK Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. UK Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. Germany Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Germany Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Germany Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. France Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 35. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 37. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 38. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 39. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. France Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 41. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 42. France Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 43. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Italy Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 46. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 47. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 48. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 50. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 51. Italy Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 52. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 53. Italy Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 54. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 55. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 56. Spain Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 57. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 58. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 59. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 60. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 61. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 62. Spain Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 63. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 64. Spain Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 65. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 66. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 67. Austria Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 68. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 69. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 70. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 71. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 72. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 73. Austria Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 74. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 75. Austria Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 76. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 77. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 78. Belgium Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 79. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 80. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 81. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 82. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 83. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 84. Belgium Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 85. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 86. Belgium Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 87. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 88. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 89. Luxembourg Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 90. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 91. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 92. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 93. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 94. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 95. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 96. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 97. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 98. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 99. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 100. The Netherlands Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 101. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 102. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 103. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 104. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 105. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 106. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 107. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 108. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 109. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 110. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 111. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 112. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 113. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 114. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 115. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 116. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 117. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 118. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 119. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 120. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 121. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 122. Organic Developments Done By Companies
  • Table 123. Inorganic Developments Done By Companies
  • Table 124. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market

List Of Figures

  • Figure 1. Europe Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
  • Figure 2. Europe Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
  • Figure 3. Europe Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Europe Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030
  • Figure 6. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
  • Figure 7. Point-of-Testing: Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Laboratory Testing: Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
  • Figure 10. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
  • Figure 11. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
  • Figure 12. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
  • Figure 13. Europe Molecular Diagnostic for Infectious Diseases Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 14. Europe Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
  • Figure 15. UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 16. Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 17. France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 18. Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 19. Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 20. Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 21. Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Rest of Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Growth Strategies Done by the Companies in the Market, (%)